D’Herelle, F. Bacteriophage as a treatment in acute medical and surgical infections. Bull. N. Y. Acad. Med. 7, 329–348 (1931).
D’Herelle, F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. Res. Microbiol. 158, 553–554 (2007).
D’Herelle, F. Studies upon asiatic cholera. Yale J. Biol. Med. 1, 195–219 (1929).
Myelnikov, D. An alternative cure: the adoption and survival of bacteriophage therapy in the USSR, 1922−1955. J. Hist. Med. Allied Sci. 73, 385–411 (2018).
Bronfenbrenner, J. & Muckenfuss, R. Studies on the bacteriophage of d’Herelle: VIII. The mechanism of lysis of dead bacteria in the presence of bacteriophage. J. Exp. Med. 45, 887–909 (1927).
Chanishvili, N. Phage therapy—history from Twort and d’Herelle through Soviet experience to current approaches. Adv. Virus Res. 83, 3–40 (2012).
Clokie, M. R., Millard, A. D., Letarov, A. V. & Heaphy, S. Phages in nature. Bacteriophage 1, 31–45 (2011).
Suttle, C. A. Marine viruses—major players in the global ecosystem. Nat. Rev. Microbiol. 5, 801–812 (2007).
Al-Shayeb, B. et al. Clades of huge phages from across Earth’s ecosystems. Nature 578, 425–431 (2020).
Youngblut, N. D. et al. Vertebrate host phylogeny influences gut archaeal diversity. Nat. Microbiol. 6, 1443–1454 (2021).
Wielscher, M. et al. The phageome in normal and inflamed human skin. Sci. Adv. 9, eadg4015 (2023).
Shkoporov, A. N. & Hill, C. Bacteriophages of the human gut: the ‘known unknown’ of the microbiome. Cell Host Microbe 25, 195–209 (2019).
Cao, Z. et al. The gut virome: a new microbiome component in health and disease. EBioMedicine 81, 104113 (2022).
Howard-Varona, C., Hargreaves, K. R., Abedon, S. T. & Sullivan, M. B. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISME J. 11, 1511–1520 (2017).
Mäntynen, S., Laanto, E., Oksanen, H. M., Poranen, M. M. & Díaz-Muñoz, S. L. Black box of phage-bacterium interactions: exploring alternative phage infection strategies. Open Biol. 11, 210188 (2021).
Phage therapy medicinal products (general chapter 5.31). In European Pharmacopoeia, 11th edn, Supplement 11.6. https://www.edqm.eu/documents/52006/277566/European%20Pharmacopoeia%20-%20Phage%20therapy%20medicinal%20products%20%285.31%29.pdf/d9da2e01-e002-32c9-b2eb-8a9360439c05?t=1727862827906 (Council of Europe, 2024).
Pirnay, J. P. et al. Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173–2179 (2015).
Suh, G. A. et al. Considerations for the use of phage therapy in clinical practice. Antimicrob. Agents Chemother. 66, e0207121 (2022).
Liu, D. et al. The safety and toxicity of phage therapy: a review of animal and clinical studies. Viruses 13, 1268 (2021).
Uyttebroek, S. et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect. Dis. 22, e208–e220 (2022).
Pirnay, J.-P. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat. Microbiol. 9, 1434–1453 (2024).
Stacey, H. J., De Soir, S. & Jones, J. D. The safety and efficacy of phage therapy: a systematic review of clinical and safety trials. Antibiotics (Basel) 11, 1340 (2022).
EudraLex − Volume 4 – Good Manufacturing Practice (GMP) guidelines. European Commission https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en (2022).
Leitner, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect. Dis. 21, 427–436 (2021).
Ooi, M. L. et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus. JAMA Otolaryngol. Head Neck Surg. 145, 723–729 (2019).
Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 19, 35–45 (2019).
Wortelboer, K. et al. Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety. Nat. Commun. 14, 5600 (2023).
Sarker, S. A. et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124–137 (2016).
Rhoads, D. D. et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18, 237–238, 240−243 (2009).
Nir-Paz, R. et al. Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers. Med 6, 100565 (2025).
Van Nieuwenhuyse, B. et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection: outcomes and phage-antibiotic interactions. Viruses 13, 1898 (2021).
Van Nieuwenhuyse, B. et al. Case report: Personalized triple phage-antibiotic combination therapy to rescue necrotizing fasciitis caused by Panton-Valentine leukocidin-producing MRSA in a 12-year-old boy. Front. Cell. Infect. Microbiol. 14, 1354681 (2024).
Chan, B. K. et al. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nat. Med. 31, 1494–1501 (2025).
Rubalskii, E. et al. Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiotics (Basel) 9, 232 (2020).
Tkhilaishvili, T. et al. Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. J. Infect. 83, e1–e3 (2021).
Alt, V. et al. Case report: Local bacteriophage therapy for fracture-related infection with polymicrobial multi-resistant bacteria: hydrogel application and postoperative phage analysis through metagenomic sequencing. Front. Med. (Lausanne) 11, 1428432 (2024).
Tkhilaishvili, T., Winkler, T., Müller, M., Perka, C. & Trampuz, A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 64, e00924-19 (2019).
Paul, K. et al. Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses 13, 1785 (2021).
Vogt, D. et al. [Beyond antibiotic therapy – Future antiinfective strategies – Update 2017]. Unfallchirurg 120, 573–584 (2017).
McCallin, S., Sacher, J. C., Zheng, J. & Chan, B. K. Current state of compassionate phage therapy. Viruses 11, 343 (2019).
Doub, J. B. et al. Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection—a case report. Acta Orthop. 93, 756–759 (2022).
Ferry, T. et al. Case report: Arthroscopic ‘debridement antibiotics and implant retention’ with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosa prosthetic knee infection. Front. Med. (Lausanne) 8, 569159 (2021).
Doub, J. B., Ng, V. Y., Wilson, E., Corsini, L. & Chan, B. K. Successful treatment of a recalcitrant staphylococcus epidermidis prosthetic knee infection with intraoperative bacteriophage therapy. Pharmaceuticals (Basel) 14, 231 (2021).
Püschel, A., Skusa, R., Bollensdorf, A. & Gross, J. Local treatment of driveline infection with bacteriophages. Antibiotics (Basel) 11, 1310 (2022).
Popescu, M., Van Belleghem, J. D., Khosravi, A. & Bollyky, P. L. Bacteriophages and the immune system. Annu. Rev. Virol. 8, 415–435 (2021).
Van Belleghem, J. D., Dąbrowska, K., Vaneechoutte, M., Barr, J. J. & Bollyky, P. L. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses 11, 10 (2018).
Sweere, J. M. et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 363, eaat9691 (2019).
Górski, A. et al. Phages and immunomodulation. Future Microbiol. 12, 905–914 (2017).
Górski, A., Międzybrodzki, R., Jończyk-Matysiak, E., Kniotek, M. & Letkiewicz, S. Therapeutic phages as modulators of the immune response: practical implications. Clin. Infect. Dis. 77, S433–S439 (2023).
Górski, A., Międzybrodzki, R., Jończyk-Matysiak, E., Żaczek, M. & Borysowski, J. Phage-specific diverse effects of bacterial viruses on the immune system. Future Microbiol. 14, 1171–1174 (2019).
Górski, A. et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41–71 (2012).
Dąbrowska, K. Interaction of bacteriophages with the immune system: induction of bacteriophage-specific antibodies. Methods Mol. Biol. 1693, 139–150 (2018).
Dabrowska, K., Switała-Jeleń, K., Opolski, A. & Górski, A. Possible association between phages, Hoc protein, and the immune system. Arch. Virol. 151, 209–215 (2006).
Zhang, T. et al. A bacterial immunity protein directly senses two disparate phage proteins. Nature 635, 728–735 (2024).
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K. & Schooley, R. T. Phage therapy: from biological mechanisms to future directions. Cell 186, 17–31 (2023).
Mitropoulou, G. et al. Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations. Eur. Respir. Rev. 31, 220121 (2022).
Międzybrodzki, R. et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73–121 (2012).
Aslam, S. Bacteriophage therapy as a treatment option for transplant infections. Curr. Opin. Infect. Dis. 33, 298–303 (2020).
Borysowski, J. & Górski, A. Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 12, 466–471 (2008).
Van Nieuwenhuyse, B. et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat. Commun. 13, 5725 (2022).
Dedrick, R. M. et al. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin. Infect. Dis. 76, 103–112 (2023).
Howard-Jones, A. R., Iredell, J. R. & Khatami, A. Phage therapy in pediatrics: the way forward for difficult-to-treat infections? Expert Rev. Anti Infect. Ther. 20, 487–491 (2022).
Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).
Khatami, A. et al. Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child. EMBO Mol. Med. 13, e13936 (2021).
Lebeaux, D. et al. A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses 13, 60 (2021).
Gainey, A. B. et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr. Pulmonol. 55, 2990–2994 (2020).
Duplessis, C. et al. Refractory Pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy. J. Pediatric Infect. Dis. Soc. 7, 253–256 (2018).
Fortuna, W., Miedzybrodzki, R., Weber-Dabrowska, B. & Górski, A. Bacteriophage therapy in children: facts and prospects. Med. Sci. Monit. 14, Ra126–Ra132 (2008).
Uhr, J. W., Dancis, J. & Finkelstein, M. S. Passage of bacteriophage phi X 174 across the placenta in guinea pigs. Proc. Soc. Exp. Biol. Med. 113, 391–394 (1963).
Kulangara, A. C. & Sellers, M. I. Passage of bacteriophages from mother to foetus in the rat. Proc. Soc. Exp. Biol. Med. 101, 207–211 (1959).
Srivastava, A. S., Chauhan, D. P. & Carrier, E. In utero detection of T7 phage after systemic administration to pregnant mice. Biotechniques 37, 81–83 (2004).
Young, G. R. et al. Optimisation and application of a novel method to identify bacteriophages in maternal milk and infant stool identifies host-phage communities within preterm infant gut. Front. Pediatr. 10, 856520 (2022).
Furfaro, L. L., Chang, B. J. & Payne, M. S. Applications for bacteriophage therapy during pregnancy and the perinatal period. Front. Microbiol. 8, 2660 (2017).
Shamash, M. & Maurice, C. F. Phages in the infant gut: a framework for virome development during early life. ISME J. 16, 323–330 (2022).
Ligonenko, O. V. et al. [Application of bacteriophages in the complex treatment of shotgun wounds of soft tissues in patients suffering from multiple antibiotic allergies]. Klin. Khir. 65−66 (2015).
Sakandelidze, V. M. [The combined use of specific phages and antibiotics in different infectious allergoses]. Vrach. Delo. 60−63 (1991).
European Committee on Antimicrobial Susceptibility Testing. EUCAST https://www.eucast.org/ast-of-phages (2026).
Phagistry. Registry for patients receiving phage therapy. https://www.phagistry.org (2026).
Nick, J. A. et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185, 1860–1874 (2022).
Bretaudeau, L., Tremblais, K., Aubrit, F., Meichenin, M. & Arnaud, I. Good Manufacturing Practice (GMP) compliance for phage therapy medicinal products. Front. Microbiol. 11, 1161 (2020).
Hietala, V., Horsma-Heikkinen, J., Carron, A., Skurnik, M. & Kiljunen, S. The removal of endo- and enterotoxins from bacteriophage preparations. Front. Microbiol. 10, 1674 (2019).
Van Belleghem, J. D., Merabishvili, M., Vergauwen, B., Lavigne, R. & Vaneechoutte, M. A comparative study of different strategies for removal of endotoxins from bacteriophage preparations. J. Microbiol. Methods 132, 153–159 (2017).
Merabishvili, M. et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4, e4944 (2009).
Luong, T., Salabarria, A. C., Edwards, R. A. & Roach, D. R. Standardized bacteriophage purification for personalized phage therapy. Nat. Protoc. 15, 2867–2890 (2020).
Concept paper on the establishment of a guideline on the development and manufacture of human medicinal products specifically designed for phage therapy. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-safety-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy_en.pdf (European Medicines Agency, 2023).
Pirnay, J. P. et al. The magistral phage. Viruses 10, 64 (2018).
Moraes de Souza, C., Tanir, T., Orellana, M., Escalante, A. & Koeris, M. S. Manufacturing bacteriophages (part 2 of 2): formulation, analytics and quality control considerations. Pharmaceuticals (Basel) 14, 895 (2021).
Rosner, D. & Clark, J. Formulations for bacteriophage therapy and the potential uses of immobilization. Pharmaceuticals (Basel) 14, 359 (2021).
Flint, R. et al. Stability considerations for bacteriophages in liquid formulations designed for nebulization. Cells 12, 2057 (2023).
Winzig, F. et al. Inhaled bacteriophage therapy for multi-drug resistant Achromobacter. Yale J. Biol. Med. 95, 413–427 (2022).
Malik, D. J. et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv. Colloid. Interface Sci. 249, 100–133 (2017).
Karthika, C., Malligarjunan, N., Pandian, S. K. & Gowrishankar, S. Chitosan-encapsulated bacteriophage cocktail as promising oral delivery system to surpass gastrointestinal infection caused by Klebsiella aerogenes. Int. J. Biol. Macromol. 292, 139236 (2025).
Barros, J. A. R. et al. Encapsulated bacteriophages in alginate-nanohydroxyapatite hydrogel as a novel delivery system to prevent orthopedic implant-associated infections. Nanomedicine 24, 102145 (2020).
Colom, J. et al. Microencapsulation with alginate/CaCO3: a strategy for improved phage therapy. Sci. Rep. 7, 41441 (2017).
Ahmadi, H., Wang, Q., Lim, L. T. & Balamurugan, S. Encapsulation of Listeriaphage A511 by alginate to improve its thermal stability. Methods Mol. Biol. 1681, 89–95 (2018).
Kielholz, T., Rohde, F., Jung, N. & Windbergs, M. Bacteriophage-loaded functional nanofibers for treatment of P. aeruginosa and S. aureus wound infections. Sci. Rep. 13, 8330 (2023).
Cinquerrui, S., Mancuso, F., Vladisavljević, G. T., Bakker, S. E. & Malik, D. J. Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front. Microbiol. 9, 2172 (2018).
Moghtader, F., Solakoglu, S. & Piskin, E. Alginate- and chitosan-modified gelatin hydrogel microbeads for delivery of E. coli phages. Gels 10, 244 (2024).
Mohan, N., Bosco, K., Peter, A., Abhitha, K. & Bhat, S. G. Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review. Arch. Microbiol. 206, 443 (2024).
Mary, A. S. et al. Formulation of dual-functional nonionic cetomacrogol creams incorporated with bacteriophage and human platelet lysate for effective targeting of MDR P. aeruginosa and enhanced wound healing. ACS Appl. Bio. Mater. 7, 6583–6593 (2024).
Chen, B. et al. Combination of bacteriophages and vancomycin in a co-delivery hydrogel for localized treatment of fracture-related infections. NPJ Biofilms Microbiomes 10, 77 (2024).
Coleman, H. J. et al. Formulation of three tailed bacteriophages by spray-drying and atomic layer deposition for thermal stability and controlled release. J. Pharm. Sci. 113, 3238–3245 (2024).
Passerini, M., Petri, F. & Suh, G. A. Phage therapy for cardiac implantable electronic devices and vascular grafts: a targeted literature review. Pathogens 13, 424 (2024).
Rojas, S. V. et al. Bacteriophage-enriched galenic for intrapericardial ventricular assist device infection. Antibiotics (Basel) 11, 602 (2022).
European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. European Commission https://health.ec.europa.eu/system/files/2016-11/2009_01_12_readability_guideline_final_en_0.pdf (2009).
US Food & Drug Administration. Bacterial Endotoxins/Pyrogens. FDA https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/bacterial-endotoxinspyrogens (2014).
Pyrogenicity (general chapter 5.1.13). In European Pharmacopoeia 11th edn (European Directorate for the Quality of Medicines & HealthCare, 2025).
Jończyk, E., Kłak, M., Międzybrodzki, R. & Górski, A. The influence of external factors on bacteriophages—review. Folia Microbiol. (Praha) 56, 191–200 (2011).
Wdowiak, M., Paczesny, J. & Raza, S. Enhancing the stability of bacteriophages using physical, chemical, and nano-based approaches: a review. Pharmaceutics 14, 1936 (2022).
Pirnay, J. P., Merabishvili, M., Van Raemdonck, H., De Vos, D. & Verbeken, G. Bacteriophage production in compliance with regulatory requirements. Methods Mol. Biol. 1693, 233–252 (2018).
König, H. & Sauter, A. Bakteriophagen in Medizin, Land- und Lebensmittelwirtschaft – Anwendungsperspektiven, Innovations- und Regulierungsfragen. Innovationsanalyse. KIT https://publikationen.bibliothek.kit.edu/1000160512 (2023).
Merabishvili, M., Pirnay, J. P. & De Vos, D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol. Biol. 1693, 99–110 (2018).
Molina, F., Menor-Flores, M., Fernández, L., Vega-Rodríguez, M. A. & García, P. Systematic analysis of putative phage-phage interactions on minimum-sized phage cocktails. Sci. Rep. 12, 2458 (2022).
Kim, M. K. et al. A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. Nat. Commun. 15, 9987 (2024).
Chan, B. K., Abedon, S. T. & Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769–783 (2013).
Rotman, S. G. et al. Local bacteriophage delivery for treatment and prevention of bacterial infections. Front. Microbiol. 11, 538060 (2020).
Niu, Y. D. et al. Efficacy of individual bacteriophages does not predict efficacy of bacteriophage cocktails for control of Escherichia coli O157. Front. Microbiol. 12, 616712 (2021).
Würstle, S. et al. Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Sci. Rep. 14, 2657 (2024).
Torres-Barceló, C., Turner, P. E. & Buckling, A. Mitigation of evolved bacterial resistance to phage therapy. Curr. Opin. Virol. 53, 101201 (2022).
Hall, A. R., De Vos, D., Friman, V. P., Pirnay, J. P. & Buckling, A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 78, 5646–5652 (2012).
Burmeister, A. R. & Turner, P. E. Trading-off and trading-up in the world of bacteria-phage evolution. Curr. Biol. 30, R1120–R1124 (2020).
Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).
Gurney, J. et al. Phage steering of antibiotic-resistance evolution in the bacterial pathogen, Pseudomonas aeruginosa. Evol. Med. Public Health 2020, 148–157 (2020).
Oromí-Bosch, A., Antani, J. D. & Turner, P. E. Developing phage therapy that overcomes the evolution of bacterial resistance. Annu. Rev. Virol. 10, 503–524 (2023).
Kortright, K. E., Chan, B. K., Koff, J. L. & Turner, P. E. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25, 219–232 (2019).
Kunisch, F. et al. Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs. Nat. Commun. 15, 8572 (2024).
Bernabéu-Gimeno, M. et al. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med 5, 1096–1111 (2024).
Międzybrodzki, R. et al. Means to facilitate the overcoming of gastric juice barrier by a therapeutic staphylococcal bacteriophage A5/80. Front. Microbiol. 8, 467 (2017).
Le Guellec, S. et al. Administration of bacteriophages via nebulization during mechanical ventilation: in vitro study and lung deposition in macaques. Viruses 15, 602 (2023).
Richter, Ł et al. Adsorption of bacteriophages on polypropylene labware affects the reproducibility of phage research. Sci. Rep. 11, 7387 (2021).
Wright, A., Hawkins, C. H., Anggård, E. E. & Harper, D. R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349–357 (2009).
Kim, P. et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect. Dis. 24, 1319–1332 (2024).
Koncz, M. et al. Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens. Cell 187, 5901–5918 (2024).
Parmar, K. et al. Interlaboratory comparison of Pseudomonas aeruginosa phage susceptibility testing. J. Clin. Microbiol. 61, e0061423 (2023).
Kolenda, C., Jourdan, J., Roussel-Gaillard, T., Medina, M. & Laurent, F. Phage susceptibility testing methods or ‘phagograms’: where do we stand and where should we go? J. Antimicrob. Chemother. 79, 2742–2749 (2024).
Khan Mirzaei, M. & Nilsson, A. S. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS ONE 10, e0118557 (2015).
Kunz Coyne, A. J. et al. Exploring synergistic and antagonistic interactions in phage-antibiotic combinations against ESKAPE pathogens. Microbiol. Spectr. 12, e0042724 (2024).
Gordillo Altamirano, F. L. et al. Phage-antibiotic combination is a superior treatment against Acinetobacter baumanniiin a preclinical study. EBioMedicine 80, 104045 (2022).
Ma, L., Green, S. I., Trautner, B. W., Ramig, R. F. & Maresso, A. W. Metals enhance the killing of bacteria by bacteriophage in human blood. Sci. Rep. 8, 2326 (2018).
Youssef, O. et al. Impact of the calcium concentration on the efficacy of phage phiIPLA-RODI, LysRODIΔAmi and nisin for the elimination of Staphylococcus aureus during lab-scale cheese production. Int. J. Food Microbiol. 399, 110227 (2023).
Bichet, M. C. et al. Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy. iScience 24, 102287 (2021).
Dedrick, R. M. et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat. Med. 27, 1357–1361 (2021).
Żaczek, M. et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 7, 1681 (2016).
Loh, B. et al. Encapsulation and delivery of therapeutic phages. Appl. Environ. Microbiol. 87, e01979-20 (2021).
Vogele, K., Falgenhauer, E., von Schönberg, S., Simmel, F. C. & Pirzer, T. Small antisense DNA-based gene silencing enables cell-free bacteriophage manipulation and genome replication. ACS Synth. Biol. 10, 459–465 (2021).
Levrier, A. et al. PHEIGES: all-cell-free phage synthesis and selection from engineered genomes. Nat. Commun. 15, 2223 (2024).
Emslander, Q. et al. Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria. Cell Chem. Biol. 29, 1434–1445 (2022).
